Open AccessPrediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy
Author(s) -
Yoshifumi Tomita,
Takeshi Takagaki,
Akihiro Kitamura,
Erika Wada,
Hironori Nishibe,
Amane Tateno,
Yoshiro Okubo
Publication year - 2022
Publication title -
journal of clinical psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.786
H-Index - 121
eISSN - 1533-712X
pISSN - 0271-0749
DOI - 10.1097/jcp.0000000000001545
Subject(s) - transdermal , transdermal patch , pharmacokinetics , pharmacology , dopamine receptor d2 , medicine , oral administration , pharmacodynamics , population , dopamine , environmental health
Blonanserin is an atypical antipsychotic, a potent selective antagonist of dopamine D2 receptor (D2), prescribed as oral formulations in patients with schizophrenia. Blonanserin transdermal patch was developed to provide a new treatment option, but the corresponding dose to oral blonanserin was not clear. The aims of this study were to clarify the pharmacokinetic (PK)-pharmacodynamic characteristics of blonanserin after transdermal patch application and to evaluate the corresponding dose to oral formulation based on striatal D2 occupancy.